Leadership growth New CEO Richard Harris appointed on Apr 30, 2026, signaling strategic leadership and potential shifts in client engagement, product focus, and market positioning that may open opportunities for expanded service scopes and new enterprise partnerships.

Global expansion Opened China headquarters in Wuxi and expanded facilities in 2026, indicating a push into Asian markets and localized capabilities that can be leveraged to pursue region-specific clinical trials, regulatory support, and logistics partnerships with local biotechs and CROs.

Strategic partnerships Recent collaborations with Slope Clinical and Teddy Laboratory (Frontage integration) suggest an ecosystem approach combining API-enabled trials and localized lab expertise, creating cross-sell opportunities for integrated central laboratory services and data-driven trial solutions.

Tech-enabled operations Emphasis on technology-driven central laboratory services with a diverse tech stack and embedded resourcing supports, presenting opportunities to upsell advanced analytics, digital sample logistics, and integration services to large pharma and biotech clients seeking end-to-end trial optimization.

Market positioning Revenue in the mid hundreds of millions and competitive positioning among major CROs and laboratory networks, indicating ripe opportunities to target mid-to-large pharma companies seeking scalable central lab solutions, partnerships, and global trial delivery capabilities.